| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $78.0M | — | +28.3% |
| SG&A Expense | $27.9M | — | +100.2% |
| Operating Income | -$105.9M | — | -41.7% |
| Net Income | -$92.6M | — | -33.6% |
| EPS (Basic) | -$3.20 | — | +2.7% |
| EPS (Diluted) | -$3.20 | — | +2.7% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $536.3M | +50.1% | +223.9% |
| Short-term Investments | $250.5M | +3.5% | — |
| Current Assets | $797.8M | +30.6% | +139.2% |
| Total Assets | $1.46B | +55.7% | +205.0% |
| Current Liabilities | $50.2M | -15.9% | +27.1% |
| Total Liabilities | $50.2M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$86.2M | — | -62.5% |
| Capital Expenditures | $62K | — | — |
| Investing Cash Flow | -$344.3M | — | -574.2% |
| Financing Cash Flow | $609.4M | — | +1023.0% |
| Free Cash Flow | -$86.2M | — | -62.6% |
| +27.1% |
| Stockholders' Equity | $1.41B | +60.6% | +221.0% |